Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Africa News Online.
Press releases published on September 4, 2025
Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina
GlobeNewswire
·
September 4, 2025
LAS VEGAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the execution of a new …
VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome (ICOMES)
GlobeNewswire
·
September 4, 2025
— Presentations spotlight VIVUS’s 13-year track record of leadership with QSYMIA® (phentermine and topiramate extended-release capsules CIV) in the treatment of obesity and overweight CAMPBELL, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a …
GoldHaven Resources Provides Exploration Update on Magno Project
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to provide an update on its exploration work program on the 100% owned Magno Project …
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
GlobeNewswire
·
September 4, 2025
Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistance Additional poster presentations highlight SCY-247’s broad spectrum of …
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
GlobeNewswire
·
September 4, 2025
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic …
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
GlobeNewswire
·
September 4, 2025
Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and clinical pipeline is supported by the innovations and …
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
GlobeNewswire
·
September 4, 2025
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced …
Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025
GlobeNewswire
·
September 4, 2025
Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by SKYLINE participants through month 36 and DAWN participants at 9 months or …
ORYZON Finalist at the 2025 European Lifestars Awards
GlobeNewswire
·
September 4, 2025
MADRID, Spain and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has been selected …
Aventis Energy Announces VTEM Survey on the Sting Copper Project
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aventis Energy (“Aventis” or the “Company”) (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce that it has engaged Geotech Ltd. (“Geotech”) and completed a VTEM (Versatile Time-Domain …
Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D
GlobeNewswire
·
September 4, 2025
AZURE-2 evaluates the efficacy and safety of brelovitug as a monotherapy compared head-to-head with Hepcludex (bulevirtide) Enrollment in AZURE-1, a global pivotal clinical trial evaluating the efficacy and safety of brelovitug compared to delayed …
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today …
Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
GlobeNewswire
·
September 4, 2025
Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action that normalizes VEGF expression. End of study, 40-week …
Robex Announces Amendments to Sprott Facility Agreement
GlobeNewswire
·
September 4, 2025
QUEBEC CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to provide an update on its US$130 million senior …
Emerita Resources Announces Increase to Loan Financing with Nebari Resources to Advance IBW Project
GlobeNewswire
·
September 4, 2025
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSXV: …
American Tungsten Progresses its IMA Mine Rehabilitation
GlobeNewswire
·
September 4, 2025
Vancouver, BC, Sept. 04, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) American Tungsten is pleased to provide an operational update, as it advances its vision to capitalize on …
Dynacor Provides Corporate Update Including Expansion Progress
GlobeNewswire
·
September 4, 2025
MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation") is pleased to provide a corporate update covering operations and progress on its expansion plan within West Africa and Latin America. Operational …
Robex Announces Voting Results for 2025 Annual General and Special Meeting of Shareholders
GlobeNewswire
·
September 4, 2025
QUEBEC CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to announce the results of the vote of its annual …
Dynacor fait le point sur ses activités, notamment sur l'avancement de son expansion
GlobeNewswire
·
September 4, 2025
MONTRÉAL, 04 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Dynacor inc. (TSX : DNG) (« Dynacor » ou la « Société ») est heureuse de fournir une mise à jour sur ses activités et les progrès réalisés dans le cadre de son plan d'expansion en Afrique de l'Ouest et en …
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
GlobeNewswire
·
September 4, 2025
SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to …